Type-specific antigens have been targeted for the detection of CTCs in breast cancer (HER-2) [57], melanoma (MEL and MCSP) [58], and OC (HE4) [31], and their detection rates (low to high) vary with each cancer type. Here, ERBB2 is linked to breast carcinoma.